Softwr

Healthcare · head to head

Beckman Coulter DxONE vs Woebot Health

Beckman Coulter DxONE logo

Beckman Coulter DxONE

Healthcare

Clinical laboratory middleware and informatics from a diagnostics instrument manufacturer

From
On request
Rated
-
Full reviewWebsite
Woebot Health logo

Woebot Health

Healthcare

Conversational CBT chatbot that withdrew from consumer distribution and now sells only to payers and providers

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Beckman Coulter DxONE the rules and quality control workflows are tuned to Beckman analysers, so laboratories with a mixed Roche, Abbott and Siemens fleet get materially less coverage and typically buy vendor neutral middleware such as Data Innovations Instrument Manager instead.; Woebot Health the company withdrew its consumer app in June 2025 after concluding FDA marketing authorisation was not achievable at acceptable cost, which is a plain signal about both regulatory position and commercial durability.
  • They diverge on capability: Beckman Coulter DxONE covers DxONE Command Central, Woebot Health covers Scripted CBT dialogue.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Beckman Coulter DxONE and Woebot Health actually diverge.

Attributes where Beckman Coulter DxONE and Woebot Health differ
AttributeBeckman Coulter DxONEWoebot Health
PlatformsWeb, WindowsiOS, Android, Web

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Beckman Coulter DxONE

  • DxONE Command Central
  • DxONE Workflow Manager
  • REMISOL Advance
  • DxONE Inventory Manager
  • Autoverification rules
  • Quality control monitoring
  • LIS interfacing

Only in Woebot Health

  • Scripted CBT dialogue
  • Mood tracking
  • Crisis routing
  • Between-session support
  • Payer deployment
  • Provider copilot positioning
  • Research licensing
  • Population reporting

What people use each for

The jobs each tool is most often brought in to do.

Beckman Coulter DxONE

  • A hospital laboratory standardising on Beckman DxC and DxI analysers that wants autoverification to release the majority of routine chemistry without technologist reviewnot Woebot Health
  • A low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules enginenot Woebot Health
  • A multi site laboratory network that needs identical autoverification rules applied consistently across every site, which REMISOL Advance is built fornot Woebot Health
  • A laboratory whose LIS cannot express delta checks or repeat rules and needs that logic to live in middleware insteadnot Woebot Health

Woebot Health

  • A health plan wanting a low intensity behavioural health option for members on a waiting list for therapynot Beckman Coulter DxONE
  • A provider organisation offering structured between-session CBT practice to patients already in treatmentnot Beckman Coulter DxONE
  • A research group running a trial that needs a clinically scripted rather than generative conversational agent for safety reasonsnot Beckman Coulter DxONE
  • A payer targeting a specific population such as postpartum members where scripted CBT content already existsnot Beckman Coulter DxONE

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Beckman Coulter DxONE

  • The rules and quality control workflows are tuned to Beckman analysers, so laboratories with a mixed Roche, Abbott and Siemens fleet get materially less coverage and typically buy vendor neutral middleware such as Data Innovations Instrument Manager instead.
  • Pricing is bundled into analyser and reagent contracts rather than itemised, so a laboratory cannot compare the informatics cost against a standalone middleware quote and often does not know what it is paying for the software.
  • Because the software is tied to a reagent rental term, the real cost of switching middleware is the remaining years of the reagent commitment, not a software renewal, which locks the laboratory in far longer than a software contract would.
  • DxONE Workflow Manager and REMISOL Advance are different products with different rule engines rather than one product at two sizes, so a laboratory that grows out of Workflow Manager faces a migration and rule rewrite, not an upgrade.
  • Interface builds to the hospital LIS are professional services work quoted per interface, and laboratories consistently underestimate this line, particularly where the LIS is an older Sunquest or SCC installation.

Woebot Health

  • The company withdrew its consumer app in June 2025 after concluding FDA marketing authorisation was not achievable at acceptable cost, which is a plain signal about both regulatory position and commercial durability.
  • It is not an FDA cleared treatment for any indication, so it cannot be positioned to members as therapy and cannot substitute for a covered behavioural health benefit.
  • The scripted, non-generative design that makes it safe also makes it feel rigid next to current conversational AI, and engagement drops off quickly once users hit the edges of the script.
  • Published evidence is short-horizon symptom change in selected populations, mostly young adults, with little evidence of durable benefit or effect at whole-population scale.
  • With consumer distribution gone, the remaining business depends on a small number of payer and provider contracts, so a buyer should assume real vendor continuity risk over a multi-year term.

Pricing, plan by plan

Beckman Coulter DxONE

On request
  • DxONE$undefined/year
    • Quoted as part of an analyser or reagent contract, not as standalone software
    • Priced against instrument fleet size and test volume
    • Multi year reagent rental agreements are the usual commercial vehicle

Woebot Health

On request
  • Woebot for payers and providers$undefined/year
    • Contracted per member per month or as a population licence
    • Sold to health plans and provider organisations, not to employers or individuals
    • No consumer purchase route since the app closed in June 2025

Which should you pick?

Choose Beckman Coulter DxONE if

  • You need dxone command central.
  • You work on Web, Windows.
  • You also want dxone workflow manager.
Beckman Coulter DxONE review

Choose Woebot Health if

  • You need scripted cbt dialogue.
  • You work on iOS, Android, Web.
  • You also want mood tracking.
Woebot Health review

Questions people ask

Is Beckman Coulter DxONE or Woebot Health better?
Neither clearly leads. Beckman Coulter DxONE starts at On request and Woebot Health at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Beckman Coulter DxONE or Woebot Health?
Beckman Coulter DxONE starts at On request and Woebot Health at On request.
Does Beckman Coulter DxONE or Woebot Health run on more platforms?
Beckman Coulter DxONE runs on Web, Windows. Woebot Health runs on iOS, Android, Web.
What is Beckman Coulter DxONE best used for?
Beckman Coulter DxONE is most often used for a hospital laboratory standardising on beckman dxc and dxi analysers that wants autoverification to release the majority of routine chemistry without technologist review, a low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules engine, a multi site laboratory network that needs identical autoverification rules applied consistently across every site, which remisol advance is built for, a laboratory whose lis cannot express delta checks or repeat rules and needs that logic to live in middleware instead. Of those, a hospital laboratory standardising on beckman dxc and dxi analysers that wants autoverification to release the majority of routine chemistry without technologist review and a low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules engine are not what Woebot Health is typically brought in for.
What can Beckman Coulter DxONE do that Woebot Health cannot?
Beckman Coulter DxONE covers DxONE Command Central, DxONE Workflow Manager, REMISOL Advance, DxONE Inventory Manager. Woebot Health covers Scripted CBT dialogue, Mood tracking, Crisis routing, Between-session support.

Answered from the vendors’ own pages

Beckman Coulter DxONE: Can I buy DxONE without buying Beckman analysers?

Not realistically. It is quoted as part of an instrument or reagent agreement and its value is in the depth of integration with Beckman platforms. A laboratory with other analysers should look at vendor neutral middleware.

Woebot Health: Is Woebot still available?

Not to consumers. The consumer app closed in June 2025. The company continues to offer the product to payers, providers and researchers.

Beckman Coulter DxONE: Is DxONE the same as REMISOL Advance?

No. REMISOL Advance is the on premises middleware for higher volume and multi site laboratories. DxONE Workflow Manager is a separate cloud product aimed at low volume laboratories. They are not the same rule engine.

Woebot Health: Is it FDA cleared?

No. It held Breakthrough Device designation but never obtained marketing authorisation, and the founder cited the cost of that pathway as the reason for closing the consumer app.

Beckman Coulter DxONE: Does Beckman publish pricing?

No. Everything is quoted, and the software cost is usually folded into a cost per reportable result on a reagent contract rather than shown as a licence fee.

Woebot Health: Is it generative AI?

Historically no. The dialogue is clinician-written and rule-based, a deliberate safety choice that limits how naturally it converses.

Beckman Coulter DxONE: Is DxONE a regulated medical device?

The middleware components carry regulatory registrations that vary by product and region. Autoverification of diagnostic results is a regulated function, so confirm the specific clearance for the module and country before deployment.

Woebot Health: What does the evidence show?

Randomised studies reported reduced depressive symptoms over short periods in selected populations, notably young adults. That is symptom change in a trial, not demonstrated population outcomes.

Share

Related pages

More on Beckman Coulter DxONE

More on Woebot Health

Keep looking

Other head to heads